Alumis Inc. (NASDAQ:ALMS - Get Free Report) major shareholder Foresite Labs, Llc purchased 25,000 shares of the firm's stock in a transaction on Friday, May 2nd. The stock was bought at an average price of $4.62 per share, with a total value of $115,500.00. Following the acquisition, the insider now owns 4,227,670 shares in the company, valued at $19,531,835.40. This trade represents a 0.59 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Foresite Labs, Llc also recently made the following trade(s):
- On Tuesday, May 6th, Foresite Labs, Llc purchased 20,000 shares of Alumis stock. The stock was acquired at an average price of $4.34 per share, for a total transaction of $86,800.00.
Alumis Stock Down 5.5 %
Shares of Alumis stock traded down $0.29 on Friday, reaching $5.03. 322,607 shares of the company were exchanged, compared to its average volume of 325,359. Alumis Inc. has a 1-year low of $3.18 and a 1-year high of $13.53. The company's 50-day moving average is $5.43 and its two-hundred day moving average is $7.21.
Analyst Ratings Changes
ALMS has been the topic of a number of recent analyst reports. Oppenheimer started coverage on Alumis in a research report on Thursday, January 30th. They issued an "outperform" rating and a $32.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $14.00 price objective on shares of Alumis in a research note on Wednesday, April 30th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a research report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $25.86.
Read Our Latest Report on ALMS
Hedge Funds Weigh In On Alumis
Several hedge funds and other institutional investors have recently modified their holdings of ALMS. Wells Fargo & Company MN boosted its stake in Alumis by 77.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock valued at $69,000 after purchasing an additional 3,823 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Alumis in the 4th quarter worth approximately $79,000. Rhumbline Advisers increased its position in Alumis by 21.7% in the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock valued at $102,000 after acquiring an additional 2,949 shares during the period. Marshall Wace LLP bought a new stake in Alumis during the 4th quarter valued at $108,000. Finally, XTX Topco Ltd bought a new position in shares of Alumis in the fourth quarter worth $129,000.
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Stories
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.